Patients’ characteristics (n=130)
| Characteristics | All (n=130) Median (range) |
| Age at start of ICI | 65 (22–95) |
| Age at onset of colitis | 65 (23–96) |
| BMI | 28 (14–53) |
| Gender | |
| Female | 48 (37%) |
| Male | 82 (63%) |
| Smoking history | |
| No | 72 (55%) |
| Yes | 58 (45%) |
| Baseline autoimmune conditions | |
| No | 107(82%) |
| Yes | 23 (18%) |
| Type of autoimmune conditions | |
| Endocrine | 10 (8%) |
| Rheumatologic | 5 (4%) |
| Gastrointestinal | 4 (3%) |
| Dermatologic | 3 (2%) |
| Neurologic | 1 (<1%) |
| Stage of melanoma | |
| III | 9 (7%) |
| IV | 121 (93%) |
| Type of primary | |
| Cutaneous | 99 (76%) |
| Mucosal | 7 (5%) |
| Ocular | 10 (8%) |
| Unknown primary | 14 (11%) |
| BRAF mutation | |
| No | 91 (70%) |
| Yes | 39 (30%) |
| Prior adjuvant therapy | |
| No | 114 (88%) |
| Yes | 16 (12%) |
| Prior systemic therapy | |
| No | 86 (66%) |
| Yes | 44 (34%) |
*Endocrine: hypothyroid (n=9), diabetes mellitus (n=1). Rheumatologic: PMR (n=2), rheumatoid arthritis (n=2), inflammatory polyarthropathy (n=1). Gastrointestinal: ulcerative colitis (n=3), celiac disease (n=1). Dermatologic: psoriasis (n=3). Neurologic: multiple sclerosis (n=1).
BMI, body mass index; ICI, immune checkpoint inhibition.